Tilray® Imports Bulk Supply of Medical Cannabis Oil into the United Kingdom

Tilray® Imports Bulk Supply of Medical Cannabis Oil into the United Kingdom

 

NANAIMO, B.C. – Tilray Inc. (NASDAQ:TLRY), a global pioneer in cannabis research, cultivation, production and distribution, today announced it has imported medical cannabis oral solutions in bulk into the United Kingdom from its Good Manufacturing Practices (GMP)-certified facility in Canada. This export allows Tilray to provide authorized U.K. patients in need with a locally maintained supply of medical cannabis oral solutions.

In September 2018, Tilray announced the successful import of Tilray 2:100 medical cannabis oil for a pediatric patient in need in the United Kingdom. Tilray’s 2:100 cannabis oil was supplied via a government-approved special access program following the U.K. Home Secretary’s historic announcement that declared prescriptions of cannabis-derived medicines legal for patients with an exceptional clinical need.

“As demand ramps up in the U.K., Tilray is well positioned to be a leading supplier of medical cannabis products,” says Sascha Mielcarek, Managing Director of Tilray Europe. “Regulations are progressing as more and more countries across Europe are recognizing the benefits of medical cannabis and its potential to improve patients’ quality of life. We’re pleased to reaffirm our commitment to delivering medical cannabis to patients in the U.K. and look forward to offering a variety of GMP-certified, pharmaceutical-grade products in the coming months.”

Tilray has six medical cannabis products approved for medical use in the U.K. that can be made available to patients with medical cannabis prescriptions obtained through private practice or the National Health Service. Tilray anticipates supplying a variety of cannabidiol (CBD)-dominant, tetrahydrocannabinol (THC)-dominant and balanced oral solutions for patients looking to use medicines derived from cannabis.

“This bulk import of Tilray medical cannabis oral solutions provides patients in need access to a sustained supply of GMP-certified, high quality medical cannabis,” says Catherine Jacobson, Tilray’s Vice President of Medical and Regulatory Affairs. “This is an important step in improving access in the U.K. Tilray will continue to advocate for reasonable patient access to medical cannabis in the U.K. and countries around the world.”

 

Tilray® Announces Support of Two New Clinical Research Studies in Australia and Canada

Tilray® Announces Support of Two New Clinical Research Studies in Australia and Canada

The Murdoch Children’s Research Institute led pilot study to evaluate the feasibility, acceptability and efficacy of cannabidiol (CBD) oral solution in reducing Severe Behavioral Problems in children with Intellectual Disabilities

 

Tilray CBD and THC capsules will be used in a study examining the safety, tolerability and effectiveness of medical cannabis on immune activation in people living with HIV being conducted by the McGill University Health Centre

Tilray® Expands Global Leadership Team with Appointment of Chief Corporate Development Officer

Former Goldman Sachs Managing Director Andrew Pucher joins Tilray to lead the company’s global corporate development activity, including M&A and corporate investments

NANAIMO, B.C. - Today, Tilray, Inc. (NASDAQ:TLRY), a global pioneer in cannabis production, research, cultivation and distribution, announces the expansion of its global senior leadership team with the appointment of Andrew Pucher as Chief Corporate Development Officer. In his new role, Andrew will lead Tilray’s corporate development function, including the team that is responsible for M&A and corporate investments. He will be based in Toronto, ON, and report to CEO Brendan Kennedy. 

Andrew joins Tilray from Goldman Sachs, where he was a Managing Director and most recently served as Head of Canadian Diversified Investment Banking, which included coverage of the Canadian cannabis industry. Previously, he was a member of Goldman Sachs’ Global Healthcare Investment Banking Group in New York, where he advised on more than $200 billion in announced M&A and financing transactions, with a focus on the biopharmaceutical sector. Andrew is a graduate of Simon Fraser University and earned a JD/MBA from York University.

Brendan Kennedy, Tilray’s CEO, said, “We’re pleased to welcome Andrew to our senior leadership team to execute strategic transactions that will further accelerate Tilray’s long-term global growth. Andrew shares our commitment to a disciplined, strategic approach in pursuing inorganic growth opportunities. His transaction experience and industry knowledge will be valuable as we work to capitalize on the many strategic opportunities available to us and continue to pursue the disruptive potential of cannabis across industries including pharmaceuticals, alcohol, consumer goods, functional food and beverage, retail and nutraceuticals.”  

Recent Tilray transactions and partnerships include: forming a global partnership with Sandoz, a division of Novartis, to distribute its medical products; establishing a 50/50 joint venture with AB InBev, the world’s largest brewer, to develop THC and CBD beverages; signing an agreement to produce THC and CBD products for Authentic Brands Group portfolio of brands, which includes Muhammed Ali, Nine West, Spyder ski gear, Prince tennis wear, Marilyn Monroe, Juicy Couture and Elvis Presley; acquiring Natura Naturals Holdings, thereby increasing its cannabis supply; and most recently, announcing the acquisition of Manitoba Harvest, the world’s largest hemp company, accelerating the company’s entry into the natural foods space with hemp and CBD-infused food and wellness products for North America.

Over the past several months, Tilray has announced appointments to its senior leadership team, with executives from world-leading brands: Sascha Mielcarek joined Tilray from Grünenthal to become Managing Director, Europe; Greg Christopher joined from Nestle to become Tilray’s EVP of Operations; Rita Seguin came on board from Diageo to be Tilray’s EVP of Human Resources; Dara Redler, Tilray’s General Counsel worked previously at The Coca-Cola Company; and Charlie Cain as VP of Retail came from Starbucks Corporation.

Tilray® Announces Successful Medical Cannabis Harvest in Portugal and Provides Update on Rapidly Expanding European Operations

NANAIMO, B.C. – Tilray, Inc. (“Tilray” or “the Company”) (NASDAQ:TLRY), a global leader in cannabis research, cultivation, production and distribution, today announced that its wholly-owned subsidiary Tilray Portugal Unipessoal Lda. (“Tilray Portugal”) has completed a successful harvest of medical cannabis at the Company’s European Union (EU) Campus in Portugal.

 

Tilray’s EU Campus in Portugal is a multi-faceted production facility that includes indoor, outdoor and greenhouse cultivation sites, as well as research labs, processing, packaging and distribution sites for medical cannabis and cannabinoid-derived medical products. To date, Tilray has invested approximately €20 million in the facility, which totals approximately 250,000 square-feet with additional room to expand. Tilray’s EU Campus also serves as a hub supporting Tilray’s clinical research and product development efforts across Europe. Tilray’s EU Campus currently employs 100 people, and that number is expected to double by the end of 2019, with production ramping up and multiple harvests anticipated in the coming months.  

 

“Our harvest in Portugal is an exciting milestone for the company as we continue to build our multinational supply chain of high-quality medical cannabis,” said Sascha Mielcarek, Managing Director, Europe. “We look forward to utilizing the capacity of Tilray Portugal to supply the medical cannabis market in Europe as we expand our operations,”

 

Tilray was the first licensed medical cannabis producer to successfully import medical cannabis products into the EU and the first licensed medical cannabis producer in North America to obtain Good Manufacturing Practice (GMP) certification in accordance with the European Medicines Agency’s (EMA) standards. Tilray has established sales and distribution arrangements to distribute medical cannabis through major pharmaceutical distribution channels throughout Germany and the European Union. The Company has also formed a global alliance with Sandoz AG, a worldwide leader in generic pharmaceuticals and biosimilars and a part of Novartis group, to increase availability of high quality medical cannabis products around the world in jurisdictions where regulations permit.

 

In addition to its EU Campus in Portugal, Tilray currently operates multiple state-of-the-art production and processing facilities in Canada. Tilray looks forward to hosting an official ribbon-cutting event at its EU Campus in Portugal later this spring.